iCamuno Biotherapeutics

iCamuno Biotherapeutics, founded in 2021, is a biotechnology company developing off-the-shelf cell therapy drugs using somatic cell reprogramming technologies. The company's co-founder, Professor Liu Xiaodong, has had research published in the journal Nature. Another co-founder is Ethan Liu, who also serves as the company's Chairman.

The firm specializes in induced pluripotent stem cell (iPSC) technologies to innovate treatments in tumor immunology and regenerative medicine. It has developed proprietary methods, including a next-generation reprogramming technique, to create enhanced pluripotent stem cells called iCam-iPSCs, which more closely resemble human embryonic stem cells in their epigenomic profile. The company leverages artificial intelligence, including an AI-driven predictive modeling system and an AI-plus-iPSC organoid platform, to guide cell differentiation and for disease modeling and drug development. This AI-driven R&D platform integrates algorithmic models to establish a systematic iPSC-based drug development pathway.

iCamuno's business model centers on developing universal, effective, and accessible cell therapies. In August 2024, the company signed a global exclusive patent license agreement with The University of Western Australia and Monash University for a novel iPSC reprogramming method called Transient Naïve Treatment (TNT). This technology is designed to correct epigenetic abnormalities in iPSCs, improving their performance, reliability, and safety. The company's pipeline includes treatments for neoplasms, immune system diseases, and nervous system diseases, with a particular focus on neurological disorders like Parkinson's disease and epilepsy. In August 2024, iCamuno, in partnership with I Peace, dosed the first patient in a clinical trial using iPSC-derived natural killer (iNK) cells for ovarian cancer immunotherapy. Preclinical programs include treatments for B-Cell Malignant Neoplasm and solid tumors.

Financially, iCamuno is a venture capital-backed company that has completed several funding rounds. In March 2026, it announced a Series A3 financing round of over RMB 100 million (approximately $14.5M), co-led by Voyagers Capital and InnoVision Capital, with continued participation from New Alliance Capital. Previous funding includes a Series A round in September 2021 for $15.4M. With a global presence, iCamuno has established R&D and clinical centers in Melbourne, Australia, R&D centers in Shanghai and Hangzhou, China, and a GMP manufacturing facility in Suzhou, China. The company also collaborates with international institutions such as Massachusetts General Hospital.

Keywords: iPSC technology, cell therapy, regenerative medicine, tumor immunology, AI-driven drug development, somatic cell reprogramming, gene editing, organoids, neurological disorders, Parkinson's disease, epilepsy, ovarian cancer, natural killer cells, Transient Naïve Treatment (TNT), iCam-iPSCs, venture capital, clinical trials, universal cell therapies, off-the-shelf therapy